A comprehensive analysis of the factors of positive pelvic lymph nodes on survival of cervical cancer patients with 2018 FIGO stage IIIC1p

References

• Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet. 2018;143(Suppl 2):22–36. doi:10.1002/ijgo.1261130306584
   PubMed Web of Science ®Google Scholar
• Matsuo K, Machida H, Mandelbaum RS, Konishi I, Mikami M. Validation of the 2018 FIGO cervical cancer staging system. Gynecol Oncol. 2019;152(1):87–93. doi:10.1016/j.ygyno.2018.10.02630389105
   PubMed Web of Science ®Google Scholar
• Sakuragi N, Satoh C, Takeda N, et al. Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with stages IB, IIA, and IIB cervical carcinoma treated with radical hysterectomy. Cancer. 1999;85(7):1547–1554. doi:10.1002/(SICI)1097-0142(19990401)85:7<1547::AID-CNCR16>3.0.CO;2-210193945
   PubMed Web of Science ®Google Scholar
• Takeda N, Sakuragi N, Takeda M, et al. Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy. Acta Obstet Gynecol Scand. 2002;81(12):1144–1151.12519111
   PubMed Web of Science ®Google Scholar
• Uno T, Ito H, Itami J, et al. Postoperative radiation therapy for stage IB-IIB carcinoma of the cervix with poor prognostic factors. Anticancer Res. 2000;20(3B):2235–2239.10928184
   PubMed Web of Science ®Google Scholar
• Lee YJ, Kim DY, Lee SW, et al. A postoperative scoring system for distant recurrence in node-positive cervical cancer patients after radical hysterectomy and pelvic lymph node dissection with para-aortic lymph node sampling or dissection. Gynecol Oncol. 2017;144(3):536–540. doi:10.1016/j.ygyno.2017.01.00128108027
   PubMed Web of Science ®Google Scholar
• Kwon J, Eom KY, Kim YS, et al. The prognostic impact of the number of metastatic lymph nodes and a new prognostic scoring system for recurrence in early-stage cervical cancer with high risk factors: a multicenter cohort study (KROG 15-04). Cancer Res Treat. 2018;50(3):964–974. doi:10.4143/crt.2017.34629081219
   PubMed Web of Science ®Google Scholar
• Aoki Y, Sasaki M, Watanabe M, et al. High-risk group in node-positive patients with stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation. Gynecol Oncol. 2000;77(2):305–309. doi:10.1006/gyno.2000.578810785483
   PubMed Web of Science ®Google Scholar
• Chen Z, Huang K, Lu Z, et al. Risk model in stage IB1-IIB cervical cancer with positive node after radical hysterectomy. Onco Targets Ther. 2016;9:3171–3179. doi:10.2147/OTT.S9415127313462
   PubMed Web of Science ®Google Scholar
• Havrilesky LJ, Leath CA, Huh W, et al. Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer. Gynecol Oncol. 2004;93(2):429–434. doi:10.1016/j.ygyno.2004.01.03815099957
   PubMed Web of Science ®Google Scholar
• Morice P, Castaigne D, Pautier P, et al. Interest of pelvic and paraaortic lymphadenectomy in patients with stage IB and II cervical carcinoma. Gynecol Oncol. 1999;73(1):106–110. doi:10.1006/gyno.1998.530810094889
   PubMed Web of Science ®Google Scholar
• Kim SM, Choi HS, Byun JS. Overall 5-year survival rate and prognostic factors in patients with stage IB and IIA cervical cancer treated by radical hysterectomy and pelvic lymph node dissection. Int J Gynecol Cancer. 2000;10(4):305–312. doi:10.1046/j.1525-1438.2000.010004305.x11240691
   PubMed Web of Science ®Google Scholar
• Lai CH, Hong JH, Hsueh S, et al. Preoperative prognostic variables and the impact of postoperative adjuvant therapy on the outcomes of stage IB or II cervical carcinoma patients with or without pelvic lymph node metastases: an analysis of 891 cases. Cancer. 1999;85(7):1537–1546.10193944
   PubMed Web of Science ®Google Scholar
• Ditto A, Martinelli F, Lo Vullo S, et al. The role of lymphadenectomy in cervical cancer patients: the significance of the number and the status of lymph nodes removed in 526 cases treated in a single institution. Ann Surg Oncol. 2013;20(12):3948–3954. doi:10.1245/s10434-013-3067-623812772
   PubMed Web of Science ®Google Scholar
• Inoue T, Morita K. The prognostic significance of number of positive nodes in cervical carcinoma stages IB, IIA, and IIB. Cancer. 1990;65(9):1923–1927.2372764
   PubMed Web of Science ®Google Scholar
• Yeh SA, Wan Leung S, Wang CJ, Chen HC. Postoperative radiotherapy in early stage carcinoma of the uterine cervix: treatment results and prognostic factors. Gynecol Oncol. 1999;72(1):10–15. doi:10.1006/gyno.1998.52179889023
   PubMed Web of Science ®Google Scholar
• Kodaira T, Fuwa N, Nakanishi T, et al. Long-term clinical outcomes of postoperative pelvic radiotherapy with or without prophylactic paraaortic irradiation for stage I-II cervical carcinoma with positive lymph nodes: retrospective analysis of predictive variables regarding survival and failure patterns. Am J Clin Oncol. 2004;27(2):140–148.15057153
   PubMed Web of Science ®Google Scholar
• Huang L, Zheng M, Liu JH, et al. Risk factors and prognosis of IB-IIB cervical carcinoma with common iliac lymph node metastasis. Chin J Cancer. 2010;29(4):431–435.20346221
   PubMedGoogle Scholar
• Tsuruga T, Fujimoto A, Kawana K, et al. Radical hysterectomy with or without para-aortic lymphadenectomy for patients with stage IB2, IIA2, and IIB cervical cancer: outcomes for a series of 308 patients. Int J Clin Oncol. 2016;21(2):359–366. doi:10.1007/s10147-015-0907-326438230
   PubMed Web of Science ®Google Scholar
• Petrelli F, De Stefani A, Raspagliesi F, Lorusso D, Barni S. Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: a systematic review and meta-analysis. Gynecol Oncol. 2014;134(1):166–171. doi:10.1016/j.ygyno.2014.04.04924793000
   PubMed Web of Science ®Google Scholar
• Mabuchi S, Isohashi F, Yokoi T, et al. A phase II study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodes. Gynecol Oncol. 2016;141(2):240–246. doi:10.1016/j.ygyno.2016.02.01126883141
   PubMed Web of Science ®Google Scholar